GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (NAS:FLGT) » Definitions » PE Ratio (TTM)

Fulgent Genetics (Fulgent Genetics) PE Ratio (TTM) : At Loss (As of Apr. 30, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Fulgent Genetics PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-30), Fulgent Genetics's share price is $20.36. Fulgent Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.64. Therefore, Fulgent Genetics's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Fulgent Genetics's PE Ratio (TTM) or its related term are showing as below:

FLGT' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: 5.08   Max: 400
Current: At Loss


During the past 10 years, the highest PE Ratio (TTM) of Fulgent Genetics was 400.00. The lowest was 0.00. And the median was 5.08.


FLGT's PE Ratio (TTM) is ranked worse than
100% of 97 companies
in the Medical Diagnostics & Research industry
Industry Median: 31.73 vs FLGT: At Loss

Fulgent Genetics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-4.30. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.64.

As of today (2024-04-30), Fulgent Genetics's share price is $20.36. Fulgent Genetics's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.06. Therefore, Fulgent Genetics's PE Ratio without NRI for today is At Loss.

During the past 10 years, Fulgent Genetics's highest PE Ratio without NRI was 475.00. The lowest was 0.00. And the median was 5.45.

Fulgent Genetics's EPS without NRI for the three months ended in Dec. 2023 was $0.28. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.06.

During the past 12 months, Fulgent Genetics's average EPS without NRI Growth Rate was -151.90% per year.

During the past 10 years, Fulgent Genetics's highest 3-Year average EPS without NRI Growth Rate was 72.90% per year. The lowest was -21.50% per year. And the median was 7.40% per year.

Fulgent Genetics's EPS (Basic) for the three months ended in Dec. 2023 was $-4.30. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.64.


Fulgent Genetics PE Ratio (TTM) Historical Data

The historical data trend for Fulgent Genetics's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics PE Ratio (TTM) Chart

Fulgent Genetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss 5.85 6.14 6.43 At Loss

Fulgent Genetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.43 At Loss At Loss At Loss At Loss

Competitive Comparison of Fulgent Genetics's PE Ratio (TTM)

For the Diagnostics & Research subindustry, Fulgent Genetics's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fulgent Genetics's PE Ratio (TTM) Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's PE Ratio (TTM) falls into.



Fulgent Genetics PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Fulgent Genetics's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=20.36/-5.640
=At Loss

Fulgent Genetics's Share Price of today is $20.36.
Fulgent Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.64.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Fulgent Genetics  (NAS:FLGT) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Fulgent Genetics PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Fulgent Genetics (Fulgent Genetics) Business Description

Traded in Other Exchanges
Address
4978 Santa Anita Avenue, Temple City, CA, USA, 91780
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Executives
Jian Xie officer: Chief Operating Officer C/O FULGENT GENETICS, INC., 4399 SANTA ANITA AVE, EL MONTE CA 91731
Hanlin Gao 10 percent owner, officer: Chief Scientific Officer 4399 SANTA ANITA AVE., EL MONTE CA 91731
Paul Kim officer: CFO and Treasurer 4399 SANTA ANITA AVE, EL MONTE CA 91731
Regina E Groves director 5751 COPLEY DRIVE, SAN DIEGO CA 92111
Leonard E Post director
Michael Nohaile director C/O BIO AI ACCELERATION COMPANY, 20 UNIVERSITY AVENUE, CAMBRIDGE MA 02138
John C Bolger director 4978 SANTA ANITA AVENUE, SUITE 205, TEMPLE CITY CA 91780
Ming Hsieh Trust 10 percent owner 4399 SANTA ANITA AVE., EL MONTE CA 91731
Linda Marsh director 100 N. STONEMAN AVE., ROOM 200, ALHAMBRA CA 91801
Ming Hsieh director, 10 percent owner, officer: President and CEO 4399 SANTA ANITA AVE., EL MONTE CA 91731
Fulgent Genetics, Inc. director 4399 SANTA ANITA AVE, EL MONTE CA 91731
Yun Yen director 1301 OAKLAWN ROAD, ARCADIA CA 91006
James Mulay director 6521 THOROUGHBRED LOOP, ODESSA FL 33556
Xi Long Usa, Inc. 10 percent owner #6 XINRUI RD., SCIENCE CITY, LUOGANG DISTRICT, GUANGZHOU CITY F4 510663